Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ticagrelor

FDA-approved product (tablet, oral), marketed as Brilinta, Ticagrelor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ticagrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Coronary artery disease
  • Myocardial infarction
  • Peripheral vascular disease
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ticagrelor in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ticagrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

    NCT06714526 · start 2025-10-07

    Registered record
    Registry ID
    NCT06714526
    Conditions
    Intracranial Atherosclerosis
    Interventions
    Point-of-Care CYP2C19 Testing; ticagrelor + aspirin; clopidogrel + aspirin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-07
    Completion
    2027-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Atherosclerosis
    InterventionPoint-of-Care CYP2C19 Testing; ticagrelor + aspirin; clopidogrel + aspirin
    PhaseNot applicable
    Registry statusRecruiting

  • IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

    NCT06451198 · start 2025-05-19

    Registered record
    Registry ID
    NCT06451198
    Conditions
    Coronary Artery Disease; Antiplatelet Drugs
    Interventions
    Indobufen; Aspirin; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-19
    Completion
    2028-12-31
    Enrolment
    2,846

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Antiplatelet Drugs
    InterventionIndobufen; Aspirin; Ticagrelor
    PhasePhase 4
    Registry statusRecruiting

  • Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

    NCT05679271 · start 2024-08-22

    Registered record
    Registry ID
    NCT05679271
    Conditions
    Pulsatile Tinnitus
    Interventions
    Venous stenting; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2027-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulsatile Tinnitus
    InterventionVenous stenting; Standard of care
    PhaseNot applicable
    Registry statusRecruiting

  • Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation

    NCT06308952 · start 2024-07-30

    Registered record
    Registry ID
    NCT06308952
    Conditions
    Cerebrovascular Event; Stent Stenosis; Ischemic Stroke; Hemorrhagic Stroke; Stent Thrombosis; Death, Brain; Endothelial Dysfunction
    Interventions
    Atorvastatin 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-30
    Completion
    2027-12-31
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrovascular Event; Stent Stenosis; Ischemic Stroke; Hemorrhagic Stroke +3 more
    InterventionAtorvastatin 20mg
    PhasePhase 4
    Registry statusRecruiting

  • Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial

    NCT05980195 · start 2024-07-16

    Registered record
    Registry ID
    NCT05980195
    Conditions
    Carotid Stenosis; Cognitive Impairment; Hyperbaric Oxygen Therapy; Stent Implantation
    Interventions
    Hyperbaric oxygen therapy; Standard medical treatment; Risk factor management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-07-16
    Completion
    2025-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarotid Stenosis; Cognitive Impairment; Hyperbaric Oxygen Therapy; Stent Implantation
    InterventionHyperbaric oxygen therapy; Standard medical treatment; Risk factor management
    PhaseNot applicable
    Registry statusUnknown

  • Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus

    NCT06013020 · start 2024-04-01

    Registered record
    Registry ID
    NCT06013020
    Conditions
    STEMI - ST Elevation Myocardial Infarction
    Interventions
    NOAC+DAPT; DAPT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-04-01
    Completion
    2027-12-31
    Enrolment
    374

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSTEMI - ST Elevation Myocardial Infarction
    InterventionNOAC+DAPT; DAPT
    PhasePhase 4
    Registry statusRecruiting

  • OCT or Angiography Guided De-escalation of DAPT

    NCT06339021 · start 2024-04-01

    Registered record
    Registry ID
    NCT06339021
    Conditions
    Optical Coherence Tomography; Dual Antiplatelet Therapy; Antiplatelet De-escalation; Neointimal Coverage; ST Elevation Myocardial Infarction
    Interventions
    OCT-guided PCI; Conventional angiography-based PCI; DAPT de-escalation; default DAPT regimen
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2024-04-01
    Completion
    2026-12-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOptical Coherence Tomography; Dual Antiplatelet Therapy; Antiplatelet De-escalation; Neointimal Coverage +1 more
    InterventionOCT-guided PCI; Conventional angiography-based PCI; DAPT de-escalation; default DAPT regimen
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis

    NCT05885932 · start 2023-08-25

    Registered record
    Registry ID
    NCT05885932
    Conditions
    Ischemic Stroke; Vertebral Artery Stenosis
    Interventions
    Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor; Aspirin and clopidogrel or ticagrelor; mono anti-platelet therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-08-25
    Completion
    2028-09-01
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Vertebral Artery Stenosis
    InterventionDrug-eluting stenting plus aspirin and clopidogrel or ticagrelor; Aspirin and clopidogrel or ticagrelor; mono anti-platelet therapy
    PhaseNot applicable
    Registry statusRecruiting

  • Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

    NCT06400940 · start 2023-08-17

    Registered record
    Registry ID
    NCT06400940
    Conditions
    Intracranial Aneurysm
    Interventions
    ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).; combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-08-17
    Completion
    2028-08
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Aneurysm
    Interventionticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).; combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
    PhasePhase 4
    Registry statusRecruiting

  • Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome

    NCT06254391 · start 2023-07-03

    Registered record
    Registry ID
    NCT06254391
    Conditions
    Myocardial Infarction; Acute Coronary Syndrome
    Interventions
    Low-dose aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-07-03
    Completion
    2025-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Acute Coronary Syndrome
    InterventionLow-dose aspirin
    PhasePhase 2
    Registry statusUnknown

  • Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

    NCT05911659 · start 2023-05-01

    Registered record
    Registry ID
    NCT05911659
    Conditions
    Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
    Interventions
    Ticagrelor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2023-06-15
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndividualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
    InterventionTicagrelor
    PhaseNot recorded
    Registry statusUnknown

  • Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

    NCT04937699 · start 2023-03-28

    Registered record
    Registry ID
    NCT04937699
    Conditions
    Acute Coronary Syndrome; Percutaneous Coronary Intervention
    Interventions
    Standard-DAPT of Ticagrelor plus aspirin; Sequential monotherapy of Ticagrelor and clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-03-28
    Completion
    2026-12-31
    Enrolment
    2,690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Percutaneous Coronary Intervention
    InterventionStandard-DAPT of Ticagrelor plus aspirin; Sequential monotherapy of Ticagrelor and clopidogrel
    PhasePhase 4
    Registry statusRecruiting

  • Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

    NCT05646394 · start 2022-07-01

    Registered record
    Registry ID
    NCT05646394
    Conditions
    Antiphospholipid Syndrome; Arterial Thrombosis
    Interventions
    Dual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-01
    Completion
    2029-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Syndrome; Arterial Thrombosis
    InterventionDual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    PhaseNot recorded
    Registry statusRecruiting

  • Antiplatelet Therapies in Patients With Depression and Coronary Disease

    NCT05821062 · start 2022-04-14

    Registered record
    Registry ID
    NCT05821062
    Conditions
    Coronary Artery Disease; Depression
    Interventions
    standard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-14
    Completion
    2024-02
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Depression
    Interventionstandard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    PhaseNot recorded
    Registry statusUnknown

  • Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome

    NCT05183178 · start 2022-02-01

    Registered record
    Registry ID
    NCT05183178
    Conditions
    Acute Coronary Syndrome
    Interventions
    Prasugrel 10 mg p.o; Ticagrelor 90 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2025-08-31
    Enrolment
    17,095

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionPrasugrel 10 mg p.o; Ticagrelor 90 mg
    PhasePhase 4
    Registry statusCompleted